Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran
Top Cited Papers
- 31 May 2009
- journal article
- research article
- Published by Elsevier BV in American Heart Journal
- Vol. 157 (5), 805-810.e2
- https://doi.org/10.1016/j.ahj.2009.02.005
Abstract
No abstract availableThis publication has 21 references indexed in Scilit:
- Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trialJournal of Thrombosis and Haemostasis, 2007
- A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trialJournal of Thrombosis and Haemostasis, 2005
- Anticoagulation InterruptusCirculation, 2004
- Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO IJournal of Thrombosis and Haemostasis, 2004
- Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trialThe Lancet, 2003
- Multiple Hypotheses Testing with WeightsScandinavian Journal of Statistics, 1997
- Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor strokeThe Lancet, 1993
- Warfarin in the Prevention of Stroke Associated with Nonrheumatic Atrial FibrillationThe New England Journal of Medicine, 1992
- Canadian atrial fibrillation anticoaguiation (CAFA) studyJournal of the American College of Cardiology, 1991
- The Effect of Low-Dose Warfarin on the Risk of Stroke in Patients with Nonrheumatic Atrial FibrillationThe New England Journal of Medicine, 1990